HYLORIS PHARMACEUTICALS SA NPV financial statements, including revenue, expenses, profit, and loss
The total revenue of 0AB6 for the last semiannual is 1.65 M EUR, and it's 42.59% higher compared to the previous semiannual. The net income of H2 23 is -9.13 M EUR.